Back Shionogi Seiyaku German شیونوگی FA Shionogi French Shionogi ID 塩野義製薬 Japanese 시오노기 제약 Korean Shionogi Russian 鹽野義製藥 Chinese
 | |
Native name | 塩野義製薬株式会社 |
|---|---|
Romanized name | Shionogi Seiyaku Kabushiki Kaisha |
| Company type | Public (K.K) |
| TYO: 4507 Nikkei 225 Component | |
| Industry | Biotechnology & Pharmaceuticals |
| Founded | Osaka, Japan (March 17, 1878) |
| Founder | Gisaburo Shiono Sr. |
| Headquarters | 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan |
Key people | |
| Products | |
| Revenue |  ¥ 426.684 billion (2022)[1] |
| ¥ 133.274 billion (2022)[1] | |
| ¥ 107.367 billion (2022)[1] | |
| Total assets | ¥ 768.120 billion (2022)[1] |
| Total equity | ¥ 1,121.878 billion (2022)[1] |
Number of employees | Consolidated : 6,082 |
| Website | Official website |
| Footnotes / references [2][3][1] | |
Shionogi & Company, Limited (塩野義製薬株式会社, Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[4]
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[5]
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.[6]
- ^ a b c d e f "Consolidated Financial Results for Fiscal Year 2022 (IFRS)" (PDF). 23 February 2023. Retrieved 27 June 2023.
- ^ "Shionogi Company Profile". Archived from the original on 28 January 2020. Retrieved 18 March 2014.
- ^ "Shionogi Annual Report 2013" (PDF). Archived (PDF) from the original on 11 July 2019. Retrieved 18 March 2014.
- ^ "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com. Archived from the original on 7 March 2014. Retrieved 18 March 2014.
- ^ "Components:Nikkei Stock Average". Nikkei Inc. Archived from the original on 14 November 2016. Retrieved 11 March 2014.
- ^ BioSpace (27 June 2023). "Shionogi buys Qpex Biopharma for $140M, expands antimicrobial pipeline – PharmaLive". Retrieved 27 June 2023.